<DOC>
	<DOCNO>NCT02227992</DOCNO>
	<brief_summary>The objective study evaluate safety effectiveness EVARREST™ Sealant Matrix ( EVARREST™ Fibrin Sealant Patch ) ( EVARREST™ ) control mild moderate soft tissue &amp; parenchymal bleeding open hepatic , abdominal , pelvic , retroperitoneal , thoracic ( non-cardiac ) surgery paediatric patient .</brief_summary>
	<brief_title>The EVARREST® Paediatric Mild/Moderate Liver Soft Tissue Bleeding Study</brief_title>
	<detailed_description>This open label , prospective , randomise , multicentre , control , clinical study compare EVARREST SURGICEL ( oxidize regenerate cellulose ( ORC ) ) ( Control ) adjunct haemostasis conventional method control mild moderate bleeding ineffective impractical surgery paediatric patient . At least 40 qualified paediatric subject appropriate mild moderate bleeding Target Bleeding Site ( TBS ) randomise 1:1 allocation ratio either EVARREST SURGICEL ( control ) . Absolute time haemostasis assess well haemostasis 4 10 minute randomisation . Enrolment stagger age ( require European Medicines Agency ( EMA ) Paediatric Committee ) . The first 36 subject enrol age ≥1 year &lt; 18 year age . Enrolment subsequent group include 4 subject 1 month ( ≥ 28 day birth ) &lt; 1 year age follow . Ongoing safety assessment ensure adequate safety monitoring occur stag enrolment . Subjects follow post-operatively hospital discharge 30 day ( +/-14 day ) post-surgery .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<criteria>Paediatric subject age ≥28 day ( ≥ 1 month ) &lt; 18 year , require nonemergent open hepatic , abdominal , retroperitoneal , pelvic thoracic ( noncardiac ) surgical procedure . ) The first 36 subject enrolled subject age ≥1 year &lt; 18 year . ii ) The next 4 subject enrolled subject age ≥28 day &lt; 1 year . The subject 's parent/legal guardian must willing give permission subject participate trial , provide write informed consent subject . In addition , assent must obtain paediatric subject possess intellectual emotional ability comprehend concept involve trial . If paediatric subject able provide assent ( due age , maturity and/or inability intellectually and/or emotionally comprehend trial ) , parent/legal guardian 's write Informed Consent subject acceptable subject include study . Presence appropriate mild moderate bleeding soft tissue hepatic parenchyma Target Bleeding Site ( TBS ) identify intraoperatively surgeon ; Ability firmly press trial treatment TBS 4 minute randomisation Subjects know intolerance blood product one component study product unwilling receive blood product ; Female subject , childbearing age ( i.e . adolescent ) , pregnant nursing ; Subject currently participate plan participate investigational device drug without prior approval Sponsor ; Subjects know , current alcohol and/or drug abuser Subjects admit trauma surgery Subjects pre intraoperative finding identify surgeon may preclude conduct study procedure . Subject TBS actively infect field ( Class III Contaminated Class IV Dirty Infected ) TBS large defect artery vein injure vascular wall require repair maintenance vessel patency would result persistent exposure EVARREST™ SURGICEL® blood flow pressure heal absorption product ; TBS major arterial bleed require suture mechanical ligation ; Bleeding site , around , proximity foramen bone , area bony confine .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Fibrin Sealant</keyword>
	<keyword>Hemostatics</keyword>
	<keyword>Coagulants</keyword>
</DOC>